medical affairs strategy

By David Richardson, Research Team Leader Post-marketing research is a growth area. An ever more cautious and stringent regulatory environment, payers that require more and more data to justify formulary approval and reimbursement, and more crowded...

By Stephanie Swanson, Strategic Marketing Manager The CEI research team is launching two new benchmarking studies that will explore the value proposition, Return-on-Investment and performance measurement of the Medical Science Liaison function. Early...

Cutting Edge Information's new customizable "MSL Data Suite" combines the company's experience in researching medical science liaison performance and MSL program management with our team's strength in providing Life Science companies with benchmarking data, analysis...

By Yanis Saradjian,Director of Consulting Our newly updated Fair-Market Value Benchmarking and Analysis service now provides medical, scientific and regulatory staff at life sciences companies with fair-market value benchmarks for thought leaders and influential...

This is the first blog entry in a two-part series on journal selection. By Ryan McGuire,Senior Research Analyst Evaluating the medical journal landscape is the first step toward making sure manuscripts find their way to the appropriate home. In fact,...

Our current review of pharmaceutical and biotechnology strategy for the new year finds that 42 percent of companies will be increasing their budgets for investigator initiated trials. Companies fund investigator initiate trials (IITs) to support additional clinical...

Country-level medical affairs budgets currently average $1.9 million across Asia, Europe, North America and South America, according to our recent benchmarking study, with pharmaceutical and biotech companies boosting their investment in medical affairs affiliates...

While sponsors maintain editorial distance from investigators' findings, they increasingly push researchers to take action on publication Published data from investigator-initiated trials (IIT) have proven extremely valuable for both scientific and commercial...

Our recent study of Phase IV Trials found that post-marketing studies are increasingly "regionalized" to better meet U.S. and European market requirements. Differences in what regulators and payers are looking for in post-approval information in Europe and...

By Elio Evangelista,Director of Research In about five weeks, pharmaceutical, biotechnology and medical device companies will have to start compiling and aggregating data on their physician expenditures to meet the requirements spelled out in the Physician...